Senesco president and CEO Leslie Browne said that they are pleased to receive this grant to support continued development of SNS01-T, company’s lead therapeutic candidate for the treatment of multiple myeloma, which is expected to enter human clinical trials in early 2011.
"This award provides non-dilutive funding that will support our efforts to address patient needs in this orphan indication."
Senesco said that it is leveraging proprietary technology that regulates programmed cell death, or apoptosis.